Story · Medicine & Biotech

Diwakar Davar Reports 55.6% Pathologic Complete Response Rate with Pembrolizumab in cSCC

1 outlet · first reported by OncoDaily on

Diwakar Davar, Co-Leader of Cancer Immunology and Immunotherapy (CII) Program at UPMC Hillman Cancer Center, shared on LinkedIn: “PD-1 blockade produces high rates of pathologic complete response (pCR) in high-risk (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Diwakar Davar Reports 55.6% Pathologic Complete Response Rate with Pembrolizumab in cSCC

    Diwakar Davar, Co-Leader of Cancer Immunology and Immunotherapy (CII) Program at UPMC Hillman Cancer Center, shared on LinkedIn: “PD-1 blockade produces high rates of pathologic complete response (pCR) in high-risk

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.